Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | JQ1 |
Indication/Tumor Type | ovarian cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | ovarian cancer | predicted - sensitive | JQ1 | Preclinical | Actionable | In a preclinical study, JQ1 suppressed CD274 (PD-L1) expression in human ovarian cancer cell lines in culture, and inhibited CD274 (PD-L1) expression in both immune cells and tumor cells in syngeneic mouse models of ovarian cancer, resulted in cytotoxic T Cell-dependent inhibition of tumor progression (PMID: 27626654). | 27626654 |
PubMed Id | Reference Title | Details |
---|---|---|
(27626654) | BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. | Full reference... |